CD8A and cancer: Here, we comprehensively evaluated immune microenvironment changes in murine syngeneic cancer models following mJX-594 treatment and found that mJX-594 potently increased CD8+ T cells, including cancer antigen-specific CD8+ T cells, and decreased immunosuppressive cells in the tumors irrespective of therapeutic efficacy.